Form D · Biotechnology

IDBiologics, Inc.

Nashville, TN · CIK 0001812623

Offering snapshot reported Mar 3, 2021 · SEC filing

Reported sold
$4.3M
Offering amount: $4.3M
Investors reported
14
Form D · investor count
Minimum accepted
$1
Reported outside-investor minimum
First sale
May 5, 2020
As reported in this filing

Fundraising history

Reported sold
Reported amount sold by Form D filing date$0$2.15M$4.3MMay 20, 2020: $3,100,000.00May 20, 2020Mar 3, 2021: $4,300,000.00Mar 3, 2021

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

  • Reported sold$3,100,000 → $4,300,000
  • Reported investors13 → 14

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Mar 3, 2021Amendment$4,300,000$1,200,000vs May 20, 202014SEC filing
May 20, 2020Initial$3,100,000No comparison13SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-367393

Source: Form D, filed Mar 3, 2021. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
James E. Crowe, Jr. Director
Charles F. Haines Director, Executive
Kenneth J. Kelley Director
Mike La Barre Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
2101 20 Th Ave South
Nashville, TN, 37212